DNMT3A and acute myeloid leukemia: In addition, Ardestani and colleagues reported that DNMT3A R882 mutations alone do not affect the clinical outcomes of AML patients, but when accompanied by FLT3-ITD mutations, overall survival was reduced, even after allo-HSCT [64].